SARS-CoV-2 antibody landscape following multiple vaccinations and infections during Omicron period
Background: Repeated COVID-19 vaccination effects on the immunogenicity, breadth, and durability of antibody responses across antigenically distinct SARS-CoV-2 variants remain incompletely understood. Method: Participants receiving >= five COVID-19 vaccine doses 2020-2025 were selected from a prospective cohort in Michigan. Serum IgG, IgM, and ACE2 percent inhibition were measured using multiplex assays. Baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific antibody durability were evaluated using regression models. Result: Twenty-one participants were included (median: seven vaccine doses). For every two-fold increase in pre-vaccination IgG concentration, post-vaccination fold-rise was 34% (95% CI: 16%-48%), 43% (95% CI: 15%-62%), and 55% (95% CI: 21%-75%) lower following monovalent, bivalent, and 2023-24 vaccination, while baseline-adjusted immunogenicity showed no significant trends across successive vaccines. Antibody landscapes demonstrated broad cross-reactivity against ancestral and Omicron variants, with similar strain-specific IgG changes across ancestral, vaccine-matched, and antigenically distant strains, but greater heterogeneity in ACE2 inhibition. Formulation-specific waning models showed significant IgG declines following monovalent and bivalent vaccination (beta = -1.03, 95% CI: -1.51 to -0.55; P<0.001 and -1.00 , 95% CI: -1.71 to -0.30; P=0.007, respectively) and ACE2 inhibition declines following monovalent vaccination, while other formulations showed less consistent changes. Despite waning, antibody levels generally remained relatively high across variants up to 300 days post-vaccination, with formulation-specific differences in durability. Conclusion: Repeated COVID-19 vaccination maintained baseline-adjusted immunogenicity and broad cross-reactive antibody responses, with formulation-specific differences in durability. Higher baseline immunity was associated with smaller post-vaccination increases, suggesting repeated boosting continues to reinforce humoral immunity despite increasingly complex immune histories.
Authors
- Arnold S. Monto (ORCID: https://orcid.org/0000-0003-3018-435X)
- Emily Toth Martin (ORCID: https://orcid.org/0000-0002-5771-8895)
- Yangyupei Yang (ORCID: https://orcid.org/0000-0002-6011-4152)
- Amy P. Callear (ORCID: https://orcid.org/0009-0009-6663-2784)
- Elie-Tino Godonou (ORCID: https://orcid.org/0009-0003-7275-9761)
- Casey L. Juntila-Raymond
- Matthew Smith
Institutions
- University of Michigan (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-18
- DOI
- https://doi.org/10.64898/2026.11.16.26368199
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- preprint